BRPI0718310A2 - Metabólitos de talarozol - Google Patents

Metabólitos de talarozol Download PDF

Info

Publication number
BRPI0718310A2
BRPI0718310A2 BRPI0718310-0A BRPI0718310A BRPI0718310A2 BR PI0718310 A2 BRPI0718310 A2 BR PI0718310A2 BR PI0718310 A BRPI0718310 A BR PI0718310A BR PI0718310 A2 BRPI0718310 A2 BR PI0718310A2
Authority
BR
Brazil
Prior art keywords
talarozol
metabolites
dose
compound according
pharmaceutically acceptable
Prior art date
Application number
BRPI0718310-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Debra Barrett
Original Assignee
Stiefel Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories filed Critical Stiefel Laboratories
Publication of BRPI0718310A2 publication Critical patent/BRPI0718310A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0718310-0A 2006-10-17 2007-10-17 Metabólitos de talarozol BRPI0718310A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (1)

Publication Number Publication Date
BRPI0718310A2 true BRPI0718310A2 (pt) 2013-11-19

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718310-0A BRPI0718310A2 (pt) 2006-10-17 2007-10-17 Metabólitos de talarozol

Country Status (10)

Country Link
US (2) US8188124B2 (https=)
EP (1) EP2114895A4 (https=)
JP (1) JP5343267B2 (https=)
KR (1) KR101419965B1 (https=)
CN (1) CN101611016B (https=)
AU (1) AU2007311026B2 (https=)
BR (1) BRPI0718310A2 (https=)
CA (1) CA2667053C (https=)
MX (1) MX2009004096A (https=)
WO (1) WO2008049027A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
EP2229434B1 (en) 2007-11-27 2011-09-07 Lifescan, Inc. Differentiation of human embryonic stem cells
KR101731474B1 (ko) 2008-02-21 2017-05-11 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
PL2310492T3 (pl) 2008-06-30 2015-12-31 Janssen Biotech Inc Różnocowanie pluripotencjalnych komórek macierzystych
MX349178B (es) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
ES2642070T3 (es) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivo de células madre pluripotentes en microportadores
ES2584053T3 (es) 2008-11-20 2016-09-23 Janssen Biotech, Inc. Métodos y composiciones para la unión de células y cultivo en sustratos planos
KR102058901B1 (ko) 2009-07-20 2019-12-24 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
EP2542667A4 (en) 2010-03-01 2013-07-31 Janssen Biotech Inc PROCESS FOR CLEANING CELLS OBTAINED FROM PLURIPOTENTIAL STEM CELLS
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
EP2611907B1 (en) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
WO2013028771A1 (en) 2011-08-23 2013-02-28 Leong Hwei Xian Reversing intestinal inflammation by inhibiting retinoic acid metabolism
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
HK1206058A1 (en) 2012-03-07 2015-12-31 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
DK3443073T3 (da) 2016-04-14 2024-09-02 Janssen Biotech Inc Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049704A1 (en) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Also Published As

Publication number Publication date
EP2114895A4 (en) 2011-06-22
AU2007311026B2 (en) 2012-05-17
WO2008049027A1 (en) 2008-04-24
AU2007311026A1 (en) 2008-04-24
JP5343267B2 (ja) 2013-11-13
CA2667053A1 (en) 2008-04-24
US20100292284A1 (en) 2010-11-18
US20120283204A1 (en) 2012-11-08
CN101611016A (zh) 2009-12-23
CA2667053C (en) 2015-04-28
CN101611016B (zh) 2012-01-25
US8399495B2 (en) 2013-03-19
EP2114895A1 (en) 2009-11-11
JP2010506953A (ja) 2010-03-04
US8188124B2 (en) 2012-05-29
KR101419965B1 (ko) 2014-07-16
MX2009004096A (es) 2009-06-16
KR20090068286A (ko) 2009-06-25

Similar Documents

Publication Publication Date Title
BRPI0718310A2 (pt) Metabólitos de talarozol
DE69732868T2 (de) Mittel gegen Juckreiz
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
KR0133686B1 (ko) 페닐 카르바메이트
EP2789612B1 (en) Derivatives of protoberberine biological alkaloids and use of same inhibiting ulcerative colitis
KR20210052507A (ko) 간 장애 치료
US20150328243A1 (en) Stilbenoid Derivatives And Their Uses
EP0615756B1 (en) Nalbuphine esters and long-acting pharmaceutical compositions containing them
US5750534A (en) Nalbuphine esters having long acting analgesic action and method of use
PT100671B (pt) Sal de l-ascorbato de 16-descarboxi-16-hidroxi-metilanfotericina b e processo para a sua preparacao
EP2987784A1 (de) Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln
EP4265607A1 (en) Aminopyridine compound and application thereof
HUP0203790A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére
US7115666B2 (en) Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
KR820001304B1 (ko) 펜아탄올아민의 제조방법
EP0063773A1 (en) Orally active tolciclate and tolnaftate
USRE32145E (en) Orally active tolciclate .[.(and tolnaftate).].
US20250281425A1 (en) Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine
KR820001303B1 (ko) 펜에탄올아민의 제조방법
WO2022175907A1 (en) Coumarin compounds and a process for preparation thereof
JPH06279287A (ja) 癌転移抑制剤
PT96283A (pt) Metodos de utilizacao de 2-isopropil-2-fenilaminovaleronitrilos como imunossupressores e vasodilatadores
JPS59128326A (ja) 抗真菌剤
US20030166516A1 (en) Methods of treating, preventing, or inhibiting inflammation with exumolide compounds
HU198390B (en) Process for producing pharmaceutical compositions containing 3-carboxy-azetidine or derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.